Amgen cholesterol drug cuts risk of first cardiac event by 25%

Amgen's cholesterol drug Repatha demonstrated a 25% reduction in major cardiovascular events for at-risk patients without prior heart attacks or strokes, marking the first PCSK9 inhibitor proven effective in primary prevention and significantly expanding its addressable market. This clinical breakthrough, detailed at the American Heart Association meeting, follows an August FDA approval broadening its use and coincides with Repatha's sales growing 33% to $2.15 billion in the first nine months of 2025. Amgen is also pursuing direct-to-consumer sales at a substantial discount, while Merck is advancing its own rival PCSK9 pill, indicating increasing competition in the segment.

Analysis

Amgen's Repatha demonstrated a significant 25% reduction in major cardiovascular events and a 36% reduction in first heart attacks for at-risk patients without prior cardiovascular disease, as presented at the AHA meeting. This marks the first time a PCSK9 inhibitor has proven effective in primary prevention, substantially expanding Repatha's addressable market beyond secondary prevention. The positive clinical data supports the U.S. FDA's August decision to broaden Repatha's approval for adults at increased risk due to uncontrolled LDL cholesterol. This expansion is crucial for payer coverage, as highlighted by Amgen's R&D chief.

Repatha's sales grew 33% year-over-year, reaching $2.15 billion in the first nine months of 2025, indicating strong commercial momentum. Amgen's strategic move to launch direct-to-consumer sales at $239 per month, nearly 60% below the $573 list price, aims to improve patient access and potentially increase market penetration, especially for cash-paying patients. This aggressive pricing strategy could also influence broader payer coverage decisions.

Despite Repatha's strong performance and expanded indications, the competitive landscape is evolving. Merck is actively developing a rival oral PCSK9 inhibitor, enlicitide decanoate, with Phase 3 data expected at the same AHA meeting. The emergence of an oral alternative could pose a future competitive threat to Repatha's injectable format, potentially fragmenting the PCSK9 inhibitor market.

Key Decisions for Investors

• Investors should monitor Amgen's ability to capitalize on Repatha's expanded primary prevention indication and the impact of its direct-to-consumer pricing strategy on sales volume and market share.
• Evaluate the upcoming data from Merck's oral PCSK9 inhibitor, enlicitide decanoate, for its potential to disrupt the market and impact Repatha's long-term growth trajectory.
• Consider Amgen's long-term outlook, as the strong clinical data, expanded label, and robust sales growth position Repatha favorably in the cardiovascular prevention market.